Interaction between CXCR4 and CCL20 pathways regulates tumor growth
Katia Beider1, Michal Abraham, Michal Begin
1Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Hospital, Jerusalem, Israel.
Plos One
|April 3, 2009
Summary
The chemokine receptor CXCR4 stimulates CCL20 production, promoting tumor cell proliferation and growth. Neutralizing CCL20 inhibits tumor growth, suggesting CCL20 antagonists as potential cancer therapeutics.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- CXCR4 and CXCL12 are overexpressed in many tumors, driving tumor development and metastasis.
- CXCL12 (SDF-1) is produced by cancer-associated fibroblasts (CAFs), while CXCR4 is on tumor cells.
- CCL20 is also overexpressed in tumors, but its specific role and regulation remain unclear.
Purpose of the Study:
- To investigate the role of the chemokine receptor CXCR4 in regulating CCL20 production.
- To determine the effects of CCL20 on tumor cell behavior, including proliferation and adhesion.
- To evaluate the therapeutic potential of targeting CCL20 in cancer treatment.
Main Methods:
- Investigated the relationship between CXCR4 and CCL20 production in tumor cells.
- Assessed the impact of CCL20 on tumor cell proliferation and collagen adhesion in vitro.
- Evaluated tumor growth and invasiveness in vivo following CCL20 overexpression.
- Utilized neutralizing antibodies against CCL20 to inhibit tumor growth in vivo.
Main Results:
- CXCR4 stimulation leads to increased production of CCL20.
- CCL20 enhances tumor cell proliferation and adhesion to collagen.
- Overexpression of CCL20 promotes tumor growth and invasiveness both in vitro and in vivo.
- CCL20-neutralizing antibodies effectively inhibit the growth of tumors overexpressing CXCR4, CCL20, or naturally expressing CCL20.
Conclusions:
- CCL20 plays a significant role in both CXCR4-dependent and -independent tumor progression.
- Targeting CCL20 and its receptor CCR6 offers a promising therapeutic strategy for various malignancies.
Related Concept Videos
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...